comprehensive -WSS

comprehensive

author：fashion 2025-08-19 12:15:41 - browse：82

Abbott's heart device TriClip on a gradient dark blue background — coverage from STAT — The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. Illustration: STAT; Photo: Courtesy Abbott

An advisory panel to the Food and Drug Administration voted in favor of a new device from Abbott meant to treat patients with tricuspid heart valve disease. All but one of the 14 panelists said the treatment’s benefits outweighed its risks. The FDA tends to follow advisory panel recommendations.

“If we can help symptoms with this at a low cost in terms of risk, I think it makes a lot of sense,” said James Blankenship, a panelist and cardiologist at the University of New Mexico.

The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. The condition impacts 1.6 million people in the United States. Symptoms include fatigue, swelling, and atypical heart rhythms. In severe cases, the condition can lead to heart failure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： JPM pitch from hospitals? Revenue streams outside of patient care

WSS

Does Paxlovid work in people vaccinated against Covid

JPM pitch from hospitals? Revenue streams outside of patient care

CVS, Rite Aid closures threaten to worsen pharmacy deserts

UnitedHealth sued over use of algorithm in Medicare Advantage plans

What is STAT's opinion section for?

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

hotspot

comprehensive

entertainment

Affirmative action in medical school literally saved lives

Experimental asthma app from Apple and Anthem shows promise

Apple is now the first public company to be valued at $3 trillion

Today's health inequities arise from racist U.S. history, say experts

The cancer drug shortage isn’t new — and neither are the solutions

Boston Scientific acquires urology company Axonics for $3.7 billion

The high cost of giving birth even with insurance

Male doctors called my cancer incurable. A female doctor showed it wasn't

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

leisure time

Allen Institute goes after foundational questions, CEO Costa says

Allen Institute goes after foundational questions, CEO Costa says

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Profiling embryos to choose those with higher IQs is almost a reality

FDA early review: GLP

Cancer diagnosis changes perspective doctor, former hospital CEO

hotspot

focus

hotspot

Wikipedia